Compare
Veru Inc. vs Sol-Gel Technologies Ltd. vs Talphera, Inc. vs Sunshine Biopharma Inc.
| Latest fiscal year | Veru Inc. VERU | Sol-Gel Technologies Ltd. SLGL | Talphera, Inc. TLPH | Sunshine Biopharma Inc. SBFM |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $19.39M | $28.0K | $36.31M |
| Revenue growth (YoY) | n/a | +68.0% | n/a | +4.1% |
| Gross margin | n/a | n/a | n/a | 33.8% |
| Operating margin | n/a | -38.9% | n/m | -17.2% |
| Net margin | n/a | -31.6% | n/m | -16.5% |
| Net income | -$22.73M | -$6.13M | -$14.29M | -$5.98M |
| EPS (Diluted) | n/a | -$2.19 | n/a | n/a |
| Operating cash flow | -$30.04M | $322.0K | -$11.36M | -$5.33M |
| Free cash flow | -$30.04M | $275.0K | n/a | -$5.51M |
| Cash & equivalents | $15.79M | $11.03M | $5.89M | n/a |
| Total assets | $29.84M | $29.92M | $29.72M | $30.08M |
| Total liabilities | $11.50M | $7.11M | $12.68M | $7.04M |
| Shareholders' equity | $18.33M | $22.81M | $17.04M | $23.04M |
| Return on year-end equity | -124.0% | -26.9% | -83.9% | -25.9% |
| Shares outstanding | 14.65M | 2.79M | 49.33M | 4.91M |
Revenue, most recent five fiscal years
| Fiscal year | Veru Inc. | Sol-Gel Technologies Ltd. | Talphera, Inc. | Sunshine Biopharma Inc. |
|---|---|---|---|---|
| Latest | $16.89M Ended 2024-09-30 | $19.39M Ended 2025-12-31 | $28.0K Ended 2025-12-31 | $36.31M Ended 2025-12-31 |
| 1 year earlier | $16.30M Ended 2023-09-30 | $11.54M Ended 2024-12-31 | $0 Ended 2024-12-31 | $34.87M Ended 2024-12-31 |
| 2 years earlier | $39.35M Ended 2022-09-30 | $1.55M Ended 2023-12-31 | $651.0K Ended 2023-12-31 | $24.09M Ended 2023-12-31 |
| 3 years earlier | $61.26M Ended 2021-09-30 | $3.88M Ended 2022-12-31 | $0 Ended 2022-12-31 | $4.35M Ended 2022-12-31 |
| 4 years earlier | $42.59M Ended 2020-09-30 | $31.27M Ended 2021-12-31 | $2.82M Ended 2021-12-31 | $228.4K Ended 2021-12-31 |